Paris, France, November 19, 2026
Sanofi, a global biopharmaceutical company, has announced that the European Commission has approved VaxRabeo (rabies virus inactivated strain Wistar) for the prevention of rabies in individuals of all age groups. The vaccine is indicated for both pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), providing protection for individuals at risk of rabies infection as well as those who may have been exposed to the virus. This marks the first marketing authorization for VaxRabeo and follows the positive opinion issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) on September 17, 2026. Developed using advanced Vero-cell manufacturing technology, VaxRabeo is designed to offer an improved formulation, longer shelf life and enhanced temperature stability compared with Sanofi’s existing rabies vaccines. The European approval represents an important milestone in the company’s vaccine development program and strengthens its portfolio of infectious disease prevention solutions.
VaxRabeo Introduces Advanced Vero-Cell Vaccine Technology
VaxRabeo is an inactivated rabies vaccine manufactured using Vero-cell technology, an established production platform used in the development of several human vaccines. The vaccine contains the inactivated rabies virus Wistar strain and is designed to stimulate the immune system to produce protective antibodies against rabies infection. According to Sanofi, the formulation has been developed to minimize the risk of allergic reactions and provide improved thermostability compared with its existing rabies vaccines. One of its important advantages is its 60-month shelf life, equivalent to five years. Additionally, the vaccine maintains stability at temperatures of up to 27°C for 96 hours before reconstitution, potentially offering greater flexibility in storage and distribution. These characteristics may be particularly valuable for healthcare systems operating in regions where maintaining conventional cold-chain conditions can be challenging. VaxRabeo also offers flexible vaccination schedules in accordance with World Health Organization (WHO) recommendations. For pre-exposure prevention, it supports a two-dose schedule, while post-exposure vaccination for previously unvaccinated individuals follows a four-dose schedule, with or without rabies immunoglobulin as clinically indicated.
Clinical Programme Demonstrates Protective Antibody Responses
The European Commission’s approval is supported by a comprehensive clinical development program comparing VaxRabeo with Sanofi’s existing standard-of-care rabies vaccines, Verorab and Imovax Rabies. The studies evaluated the vaccine in both pre-exposure and post-exposure settings across different age groups and WHO-recommended vaccination schedules. In pre-exposure studies, VaxRabeo demonstrated comparable protective antibody levels to the existing vaccines following both two-dose and three-dose vaccination regimens in adults and children. The clinical program also evaluated booster responses administered 12 months or 24–36 months after the final pre-exposure vaccination. Results demonstrated high boostability, indicating that participants were able to mount strong antibody responses following booster administration. In post-exposure studies, VaxRabeo demonstrated a similar immunogenicity profile to Sanofi’s existing vaccines, whether administered with or without rabies immunoglobulins. Importantly, 100% of participants achieved protective antibody levels following intramuscular administration in the reported PEP studies. Across the clinical studies, VaxRabeo demonstrated an acceptable safety profile consistent with existing rabies vaccines, was generally well tolerated and showed no significant new safety concerns. These findings supported its authorization for rabies prevention across all age groups in the European Union.
New Vaccine Addresses a Major Global Health Challenge
Rabies remains one of the world’s most serious vaccine-preventable infectious diseases. According to World Health Organization estimates cited by Sanofi, the disease is present in approximately 150 countries and causes around 59,000 deaths annually worldwide. Rabies is a viral zoonotic infection that affects the central nervous system and is transmitted primarily through the saliva of infected animals, particularly through dog bites and scratches. Other mammals, including cats, bats, foxes and mongooses, can also transmit the infection. Once clinical symptoms develop, rabies is almost always fatal, making timely vaccination following potential exposure essential. Approximately 29 million people receive post-exposure rabies vaccination every year, highlighting the continued global need for accessible and effective preventive vaccines. Children are particularly vulnerable, accounting for approximately 40% of people bitten by animals suspected of having rabies who are under 15 years of age. Sanofi’s VaxRabeo approval could strengthen available vaccination options and support healthcare systems in addressing this continuing public health challenge.
The approval also reflects Sanofi’s longstanding commitment to infectious disease prevention, supported by more than five decades of experience in rabies vaccine development. By combining established Vero-cell manufacturing technology with improved storage characteristics and flexible vaccination schedules, VaxRabeo represents an important addition to the company’s global vaccine portfolio. Overall, the European authorization highlights continued innovation in vaccine formulation, manufacturing and immunization strategies aimed at improving protection against serious infectious diseases.
Source: Sanofi press release



